>>Description of the research protocol "DMA"

A phase 2, randomised, single-masked, active controlled, multicentre study to evaluate the efficacy and safety of intravitreal THR-317 administred in combination with ranibizumab, for the treatment of diabetic macular oedema (DMA).
Phase II study| Status : Ongoing (but closed to recruitment)

Additional details

Indication (or studied pathology) : Ophtamologie Rétine
Brugmann identifier : DMA
EudraCT identifier : 2017-003897-15


Involved department : Ophthalmology
Principal investigator : Postelmans
Sponsor : Thrombogenics
Contact : Clinical Research Unit

>This protocol was approved by the UZ Leuven ethics committee.